King's MND Care and Research Centre

Contact information:

Emma Willey (Coordinator): [email protected]
Rachel Tuck (Administrator): [email protected]
Ammar Al-Chalabi (Director): [email protected]
Cathy Ellis (Deputy Director): [email protected]

Tel: +44 20 7848 5192
Fax: +44 20 7848 5190

ALS Clinic:

We see ~250 new patients with motor nerve problems and follow-up around 500 per year. In addition to a tertiary diagnostic service and multidisciplinary treatment service, we provide counselling, advice on a range of inherited motor neuron disorders including ALS, hereditary spastic paraplegia, hereditary motor neuronopathy, Kennedy's disease and spinal muscular atrophy, and advice on financial and social support available.

Clinical Team
Professor Nigel Leigh (Neurologist)
Professor Christopher Shaw (Neurologist)
Professor Ammar Al-Chalabi (Neurologist)
Dr Cathy Ellis (Neurologist)
Dr Rachel Burman (Palliative Care Specialist)
Dr Rebecca Lyall (Respiratory Medicine)
Nursing
Emma Willey (Clinical Nurse Specialist)
Mary-Ann Ampong (Clinical Nurse Specialist)
Andrew Dougherty (DeNDRoN Nurse)
Barbara Coote (Research Nurse - DNA Bank)
Therapists
Julia Johnson (Speech and Language Therapy)
Gemma Downes (Physiotherapy)
Pauline Miller (Occupational Therapy)
Alan Rio (Dietician)
Clinical Trials Team
Sadaf Naz Khan (Clinical trials administrator)
Marie Thornhill (Coordinator)
Laura Monje Garcia (Nurse)
Caroline Parsley (Nurse)
Carlos Guevara (Clinician)
Administration
Rachel Tuck (Administrator)

Clinic
New patients - Thursday
Follow-up patients - Thursday morning

Research Lines:

  • Epidemiology (population register and epidemiological risk factors)
  • Phenomics (phenotypic classifications and interactions with epidemiology)
  • Genetics (linkage, GWAS, candidate gene and whole exome studies)
  • Transcriptomics (RNA expression and sequencing)
  • Proteomics (biomarker profiles)
  • Cell models (mechanisms and therapy design including SOD1, VAPB, TDP43 and FUS)
  • Clinical trials
  • Neuropsychology
  • Imaging (diagnostic and biomarker)
  • Electrophysiology
  • Therapeutic interventions (timing, choices and outcomes of NIV, gastrostomy etc).

Top 10 Publications:

  1. Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-11 (2009).
  2. Wijesekera, L.C. et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 72, 1087-94 (2009).
  3. Simpson, C.L. et al. Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Hum Mol Genet 18, 472-81 (2009).
  4. Landers, J.E. et al. Reduced expression of the kinesin-associated protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences 106, 9004-9009 (2009).
  5. Sreedharan, J. et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668-72 (2008).
  6. Abhinav, K. et al. Amyotrophic lateral sclerosis in South-East England: a population-based study. The South-East England register for amyotrophic lateral sclerosis (SEALS Registry). Neuroepidemiology 29, 44-8 (2007).
  7. Vance, C. et al. Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 129, 868-76 (2006).
  8. Turner, M.R. et al. [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain 128, 896-905 (2005).
  9. Simpson, C.L. et al. A central resource for accurate allele frequency estimation from pooled DNA genotyped on DNA microarrays. Nucleic Acids Res 33, e25 (2005).
  10. Ruddy, D.M. et al. Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q. Am J Hum Genet 73, 390-6 (2003).